VM:CC - Voyageur Pharmaceuticals Ltd. Files Interim Financial Statements and Grants Deferred Share Units

(TheNewswire)

Calgary, AB - TheNewswire - April 28, 2023 -Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (USA:VYYRF) (the " Company " or" Voyageur ") announces that it has filed its interim financialstatements and management's discussion and analysis for the quarterended February 28, 2023 on SEDAR.

The Company also announces that on April 10, 2023, itissued 328,675 Deferred Share Units ("DSUs") to directors ofthe Company pursuant to its fixed 10% equity incentive compensationplan (the "Plan").  Each DSU represents a right of theholder to receive one common share ("Common Share") of theCompany effective as of the date that the holder ceases service as adirector of the Company. The DSUs are used to compensate directors ofthe Corporation for their annual retainers and are issued quarterlyusing a deemed value that is equal to the weighted average share priceduring that quarter. The DSUs do not have an exercise price but have astarting value equal to approximately $0.095 per DSU, based on theweighted average share price for the quarter ended December 31, 2022.The DSUs are subject to the terms of the Plan and the policies of theTSX Venture Exchange (the "Exchange").  The DSUs and anyCommon Shares issued pursuant to the exercise of the DSUs are subjectto a four month hold in accordance with the policies of theExchange.

About Voyageur

Voyageur is a Canadian public company listed on theTSXV under the trading symbol VM. Voyageur is focused on thedevelopment of barium and iodine Active Pharmaceutical Ingredients(“API”) and high-performance cost-effective imaging contrastagents for the medical imaging marketplace. Voyageur’s goal is tofully integrate the barium and iodine contrast market by producing itsown minerals of barium and iodine. The business plan is to initiallygenerate cash flow from operations using third party GMPpharmaceutical manufacturers in Canada and validate the products forregulatory agencies globally. Then transitioning into a high margindomestic manufacturer of radiology drugs. Voyageur has plans to buildcarbon neutral infrastructure to become 100% self-sufficient acrossall manufacturing activities. Voyageur owns a 100% interest in threebarium sulphate (barite) projects including the Frances Creekproperty, suitable in grade for the pharmaceutical marketplace, withadditional interests in a high-grade iodine, lithium & brominebrine project located in Utah, USA. Voyageur is moving forward withits business plan of becoming the only fully integrated carbon neutralcompany in the radiology contrast media drug market, by controllingall primary input costs under the motto of:

"From the Earth to theBottle".

Neither the TSX Venture Exchange norits Regulation Services Provider (as that term is defined in thepolicies of the TSX Venture Exchange) accepts responsibility for theadequacy or accuracy of this news release.

Cautionary Statement Regarding“Forward-Looking” Information

This news releasemay contain certain forward-looking information and statementsincluding statements regarding the DSUs. All statements includedherein, other than statements of historical fact, are forward-lookinginformation and such information involves various risks anduncertainties. There can be no assurance that such information willprove to be accurate, and actual results and future events coulddiffer materially from those anticipated in such information. Adescription of assumptions used to develop such forward-lookinginformation and a description of risk factors that may cause actualresults to differ materially from forward-looking information can befound in the Company's disclosure documents on the SEDAR website atwww.sedar.com. Voyageur does not undertake to update anyforward-looking information except in accordance with applicablesecurities laws.

Copyright (c) 2023 TheNewswire - All rights reserved.